Data / Drug companies / Selegiline hydrochloride
Selegiline hydrochloride: 12 companies and 14 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Selegiline hydrochloride is listed in the FDA National Drug Code Directory by 12 companies, with 14 products in commercial distribution. 13 of the products (92.9%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule; tablet; tablet, orally disintegrating, and the newest product started marketing on March 15, 2024.
The request: Get every company that lists selegiline hydrochloride in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 12
- Products
- 14
- Generic (ANDA) products
- 13 (92.9%)
- Application numbers
- 7
- Routes
- Oral
- Brand names
- Zelapar
- openFDA record search
- api.fda.gov
Companies that list selegiline hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Apotex Corp. | 2 | capsule; tablet | Generic drugs (ANDA) | July 15, 1997 |
| Bryant Ranch Prepack | 2 | capsule | Generic drugs (ANDA) | April 1, 2021 |
| A-S Medication Solutions | 1 | tablet | Generic drugs (ANDA) | July 6, 1997 |
| A2A Integrated Pharmaceuticals | 1 | tablet | Generic drugs (ANDA) | March 15, 2024 |
| Ani Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | April 1, 2021 |
| Bausch Health US LLC | 1 | tablet, orally disintegrating | New drug applications (NDA) | June 14, 2006 |
| Chartwell RX, LLC | 1 | tablet | Generic drugs (ANDA) | August 2, 1996 |
| Golden State Medical Supply, Inc. | 1 | tablet | Generic drugs (ANDA) | June 6, 1997 |
| I3 Pharmaceuticals, LLC | 1 | tablet | Generic drugs (ANDA) | December 15, 2021 |
| Marlex Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | May 1, 2021 |
| Proficient Rx LP | 1 | capsule | Generic drugs (ANDA) | April 2, 2019 |
| Rising Pharma Holdings, Inc. | 1 | capsule | Generic drugs (ANDA) | April 2, 2019 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 7 | 50% |
| Tablet | 6 | 42.9% |
| Tablet, orally disintegrating | 1 | 7.1% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 13 | 92.9% |
| New drug applications (NDA) | 1 | 7.1% |
Pharmacologic classes
| Class | Products |
|---|---|
| Monoamine Oxidase Inhibitor | 14 |
| Monoamine Oxidase Type B Inhibitor | 14 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.